Treating hair loss with finasteride, dutasteride and minoxidil, as well as micro-needling, potentially using research chemicals such as Pyril and Senzu Beans.
The user is considering switching from finasteride to dutasteride and possibly using oral minoxidil to address hair loss, having seen some progress with topical treatments and microneedling. They are also contemplating a hair transplant in the future and seeking advice on obtaining medications in Italy.
The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.
A 22-year-old is using dutasteride and oral minoxidil for hair loss but is not seeing improvements and is considering adding pyrilumatide and microneedling. Suggestions include trying topical minoxidil, microneedling, and Nizoral shampoo, with a possible future hair transplant.
The user is experiencing erectile dysfunction and emotional numbness, possibly due to using Dutasteride for hair loss, and is considering switching back to Finasteride. They are seeking advice on whether this change might resolve their symptoms.
A dutasteride simulator predicts that daily 0.5 mg dosing results in higher DHT suppression compared to less frequent dosing. Twice-weekly dutasteride may be as effective as finasteride 5 mg, providing a balance between efficacy and ease of use.
Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.
Pyrilutamide's systemic degradation is unclear, unlike fluridil, which becomes inactive in the body. The discussion focuses on whether pyrilutamide shares this property.
PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hair follicles, potentially offering a long-term solution, though not a permanent cure.
The user is switching from oral to DIY topical finasteride due to side effects and is using a solution with 10 mg finasteride in a 100 mL mixture. They are concerned about the effectiveness of the formula due to white sediment forming in the solution.
Minoxidil is highly toxic to pets, particularly cats and dogs, and there is a call for proper labeling to warn pet owners. Despite some skepticism about the effectiveness of petitions, many agree that awareness and caution are necessary to prevent accidental poisoning.
GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.
The conversation is about making a 20mg/ml RU58841 solution for hair loss treatment using ethanol and propylene glycol. The user receives advice on calculating the correct amount of RU58841 powder needed.
A user has been using finasteride and minoxidil for hair loss without success and is considering switching to dutasteride. They are concerned about low DHT levels and are seeking advice on how to implement dutasteride effectively.
Dutasteride mesotherapy, combined with peptides and exosomes, is being considered for hair loss treatment. One user suggests that oral finasteride or dutasteride mesotherapy may not be necessary if already taking oral dutasteride.
A user started using homemade topical finasteride with PG-free liquid minoxidil for hair loss. They noticed the solution became milky with floaters and asked if it needed filtering.
A user is seeking topical versions of minoxidil and finasteride in Australia that do not contain propylene glycol. They are looking for alternatives due to potential irritation from propylene glycol.
A user shared progress pictures after 5 months of using 1mg finasteride daily, 1ml minoxidil topically every night, and 1.5mm microneedling weekly. Responses included skepticism and congratulations.
The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
Folligenz liposomal minoxidil sulfate is being discussed for its effectiveness and cost, with users comparing it to regular minoxidil and tretinoin. One user found no difference with the 10% version and noted that a lower tretinoin percentage reduced side effects like skin peeling.
After over a year of treatment with daily oral dutasteride and minoxidil, plus injected dutasteride every 6 months, the user is happy with the increased thickness of their hair and improved self-esteem, although scalp visibility remains. They encourage others to follow similar treatments for long-term hair maintenance.
A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
The conversation is about someone who has been using finasteride and minoxidil for over three years without satisfactory results for hair thinning. They have started using dutasteride and added RU58841 seven months ago but have not seen improvements yet.
Hair loss discussion includes using stemoxydine mixed with finasteride tablets as a topical treatment. One user reports positive results with healthy hair and new growth in hairline.
The user experienced severe hair shedding despite using oral finasteride, minoxidil, dutasteride, and RU58841, and was diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD). They are considering switching to topical treatments due to the ineffectiveness of their current regimen.
The conversation is about making topical finasteride using stemoxydine as a carrier. The user is considering buying Redken Cerafill Hair Re-Densifying Treatment (Stemoxydine) 90ml for this purpose.
A user experienced significant hair shedding after 8 months of using oral dutasteride (0.5 mg), minoxidil (2.5 mg), and biotin (5 mg) daily. They are concerned about the effectiveness of the treatment and possible resistance to dutasteride.
Dr. Bloxham's new channel will discuss verteporfin and other future hair loss treatments. Users express interest and hope for the effectiveness of these treatments.